Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Blog of the week

 

FREE BLOG What does the US investigation into Germany mean for pharma?

The US has launched a Section 301 trade investigation into Germany's pharmaceutical pricing policies, arguing that Americans pay around four times more for branded medicines than patients in Germany. A public hearing is scheduled for September, and the investigation could lead to additional tariffs.

FREE BLOG Are we ready to embrace robots in hospitals and care homes? 

Last night I was invited to the French Embassy in London by the trade body, Business France, to watch England narrowly win against the Democratic Republic of Congo. Predicting that it would be a nerve-wracking display, they had kindly organised some showcases of French SMEs to listen to and be inspired by.  Many others and I were rather taken by Miroki, a three and a half foot tall, bright orange, fox-like robot developed by Paris-based start-up, Enchanted Tools.

FREE BLOG What determines success or failure in AI initiatives?

Two weeks ago HBI hosted a webinar on the topic of ‘Value creation in healthcare organisations’, with lots of interesting discussion and insights from Ilmarin Schietzel, CEO of German physiotherapy chain United Therapy, and Klaus Boehncke, Global Digital Health Lead at consulting firm L.E.K. Consulting.

FREE BLOG Europe’s for-profit hospital market in 2026

We’re about to publish an updated Market Overview for Europe’s for-profit hospital sector on HBI Intelligence. This delves into the major on-going trends, challenges and opportunities facing the sector, and includes dedicated country sections including key data points such as market sizes, (CAGR) growth rates, payor splits, and top players and their market shares for some of the biggest and most interesting hospital markets: Germany, France, the UK, Italy, Spain, Portugal, Poland, Greece, and Ireland.

FREE BLOG Does medicinal cannabis need a pharmaceutical rebrand?

Yesterday I attended Cannabis Europa at the Barbican in London. This is an annual conference focused on Europe’s medicinal cannabis industry held by Prohibition Partners (a B2B market intelligence and events business). The overarching theme from panel discussions was that the nascent cannabis industry being built in Europe is different from the “wild west” one that has taken root in the US, where the line between medicinal and recreational use tends to be seen as little more than a bureaucratic formality.

Find Us